The public limited company known as Bicycle Therapeutics (NASDAQ: BCYC) Analysts from Cantor Fitzgerald provided their projections for Bicycle Therapeutics’ shares’ earnings per share (EPS) for the fiscal year 2022 in a research report that was disseminated on September 21 to customers and investors. The report was titled “Bicycle Therapeutics Shares Earnings Per Share 2022 Outlook.” L. Watsek of Cantor Fitzgerald has projected that the company will earn $3.52 per share over the next year. As a result, Cantor Fitzgerald has assigned an “Overweight” rating to the stock on their research platform. Bicycle Therapeutics’ current profit forecast for the entire year is $3.83 per share, an increase from the previous projection. According to the projections made by Cantor Fitzgerald, Bicycle Therapeutics’ earnings per share for the fiscal year 2023 will come in at $4.22.
Several other analysts have recently provided their opinions regarding the company. The “buy” rating and $65.00 target price that HC had previously assigned to Bicycle Therapeutics were lowered to $57,000 in a research note published by the company on Friday, August 5. The research note was written about Bicycle Therapeutics. In a research report published on September 12, Morgan Stanley downgraded their “equal weight” rating on Bicycle Therapeutics and dropped their price objective for the company from $60.00 to $45.00. In a research note published on Wednesday, July 6, Canaccord Genuity Group reaffirmed their “buy” rating on shares of Bicycle Therapeutics and set a price objective of $60.00 for the stock. The note also included a price objective of $60.00. In a research report published on Thursday, September 8, JMP Securities reaffirmed their “buy” rating on shares of Bicycle Therapeutics and outlined a price objective of $70.00 for the stock. JMP Securities published the report. In a research note distributed on August 22, SVB Leerink was given an “outperform” rating. Before this point, the business had been rated “market perform.” Although only two analysts have recommended maintaining their hold positions on the stock, thirteen analysts have given the stock a buy rating. According to information made available by Bloomberg, the company is currently rated as having a “Moderate Buy” as the average recommendation, and the average price target is $55.92.
On Friday, the NASDAQ: BCYC stock was first offered for trading for $24.11 per share. The stock’s moving average price over the last 50 days is $24.58, and over the last 200 days, it has been at $25.01. The company’s price-to-earnings ratio is -7.90, and its beta value is equal to 0.71. The current value of the business on the market is $715.49 million. The quick ratio is 9.88, the current ratio is also 9.88, and the debt-to-equity ratio is 0.10. The price of Bicycle Therapeutics has ranged from $12.08 to $62.08 over the previous 52 weeks, with an average price of $12.08.
On August 4, the most recent earnings report for Bicycle Therapeutics was made public. Bicycle Therapeutics shares are traded on the NASDAQ under the ticker symbol BCYC. The company reported earnings per share for the quarter of $0.90, which fell short of industry experts’ expectations, who had anticipated earnings per share of $0.85 for the period. Industry experts had forecasted that the company would report earnings per share. In addition, bicycle Therapeutics disclosed in its financial statements that its return on equity was negative by 30.07% and its net margin was negative by 530.03%. These figures were taken from their financial statements.
Recently, institutional investors and hedge funds adjusted the percentage of the company’s stock they held in their portfolios to better align with their investment strategies. Deep Track Capital LP achieved a 68.7% increase in the proportion of its holdings allocated to Bicycle Therapeutics during the first three months of 2018. Deep Track Capital LP now holds a total of 1,855,993 shares of the company’s stock, which has a current value of $81,441,000 after the purchase of an additional 755,993 shares during the most recent quarter. In addition, RTW Investments LP increased its holdings in Bicycle Therapeutics by 46.8 percent during the first three months of 2018. RTW Investments LP now has 1,276,276 shares of the company following the purchase of an additional 407,005 in the most recent quarter. The current value of RTW Investments LP’s stock holdings is $56,003,000. During the second quarter, Samlyn Capital LLC achieved a 143.9% increase in the proportion of Bicycle Therapeutics stock it owned. Samlyn Capital LLC has increased the value of its holdings to $17,456,000 by purchasing an additional 613,696 shares of the company’s stock since the beginning of this quarter. This brings the total value of its holdings to $17,456,000. In addition, Candriam S.C.A. made a new investment in Bicycle Therapeutics during the second quarter by purchasing approximately $14,006,000 per share. And finally, during the second quarter, Sio Capital Management LLC increased the amount of Bicycle Therapeutics stock owned by a percentage of 1,205.2% higher than before. After making additional purchases totaling 636,201 shares during the most recent quarter, Sio Capital Management LLC now holds 688,989 of the company’s shares in its portfolio. There is a total value of $11,561,000 associated with these shares. Institutional investors and hedge funds hold 76.45% of the total number of shares in the company, making up the majority of the shareholders.
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that develops drugs to treat diseases for which there is a demand for more treatment options. The company is headquartered in the United Kingdom. The company’s primary focus is on the product candidate known as bicycle toxin conjugate, or BTC for short. In addition, it is being investigated in cancers expressing Membrane Type 1 matrix metalloprotease as part of clinical research currently in Phase I/Ia stage.